P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy
Open Access
- 1 April 2004
- journal article
- review article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (4), 1073-1081
- https://doi.org/10.1128/aac.48.4.1073-1081.2004
Abstract
No abstract availableThis publication has 156 references indexed in Scilit:
- St John's Wort increases expression of P‐glycoprotein: Implications for drug interactionsBritish Journal of Clinical Pharmacology, 2002
- Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitorsAIDS, 2000
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV InfectionClinical Pharmacokinetics, 1999
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- What have we learnt thus far from mice with disrupted P-glycoprotein genes?European Journal Of Cancer, 1996
- The role of the MDR protein in altered drug translocation across tumor cell membranesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1995
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Journal of Clinical Investigation, 1995
- Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cellsCancer Immunology, Immunotherapy, 1993
- Human immunodeficiency virus I-induced expression of P-glycoproteinBiochemical and Biophysical Research Communications, 1990
- Reversal of multi‐drug resistance in human KB cell lines by structural analogs of verapamilInternational Journal of Cancer, 1990